Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study
- Conditions
- Rectal Cancer
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2021-03-12
- Lead Sponsor
- howard safran
- Target Recruit Count
- 7
- Registration Number
- NCT02550743
- Locations
- 🇺🇸
Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island, United States
Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease
- Conditions
- Non-small Cell Lung CancerMetastatic Lung CancerNSCLCLung Cancer
- Interventions
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- howard safran
- Target Recruit Count
- 10
- Registration Number
- NCT02469701
- Locations
- 🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States
🇺🇸The Miriam Hospital, Providence, Rhode Island, United States
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
- Conditions
- Head and Neck CancerColon Cancer
- Interventions
- Drug: Head and neckDrug: Colon- Closed as of May 2014
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- howard safran
- Target Recruit Count
- 23
- Registration Number
- NCT01744340
- Locations
- 🇺🇸
Montefiore, Bronx, New York, United States
🇺🇸Memorial Hospital, Pawtucket, Rhode Island, United States
🇺🇸Rhode Island Hospital, Providence, Rhode Island, United States
Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen
- Conditions
- Gastric CancerGastrooesophageal CancerEsophageal
- Interventions
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- howard safran
- Target Recruit Count
- 15
- Registration Number
- NCT01365130
- Locations
- 🇺🇸
Memorial Hospital, Pawtucket, Rhode Island, United States
🇺🇸Brown University Oncology Research Group, Providence, Rhode Island, United States
🇺🇸Roger Williams, Providence, Rhode Island, United States
RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- Interventions
- Drug: RAD001(Afinitor)
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- howard safran
- Target Recruit Count
- 3
- Registration Number
- NCT01057277
- Locations
- 🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States
- Prev
- 1
- 2
- Next